Eli Lilly And Stock Hits New 52-Week High (LLY)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Eli Lilly and Company (NYSE: LLY) hit a new 52-week high Friday as it is currently trading at $47.66, above its previous 52-week high of $47.26 with 3.7 million shares traded as of 1:30 p.m. ET. Average volume has been seven million shares over the past 30 days.

Eli Lilly and has a market cap of $54.38 billion and is part of the health care sector and drugs industry. Shares are up 12.8% year to date as of the close of trading on Thursday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has a P/E ratio of 13, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. You can view the full Eli Lilly and Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief